Member Spotlight: Ensign Pharmaceutical
For our June Member Spotlight we talked to Ensign Pharmaceutical, a Nebraska-based startup company on a mission to develop and market novel pharmaceutical products for the treatment of osteoarthritis and related musculoskeletal disorders.
Temporary Work Opportunity with Streck
Streck, a member of Bio Nebraska, is currently offering temporary employment opportunities to inspect goods/commodities on a short-term basis at their Omaha-based warehouse facility.
ADM corn processing plant in Nebraska to send CO2 to Wyoming Sequestration Hub
ADM, a member of Bio Nebraska, has entered into an agreement to have CO2 captured from its Columbus, Neb. corn-processing complex by Tallgrass, an energy infrastructure company.
Recap: 2022 Life Sciences on the Links Golf Scramble
Bio Nebraska hosted over 30 teams for its 2022 Life Sciences on the Links Golf Scramble.
Novozymes celebrates a decade of growth and impact in Nebraska
Novozymes, a member of Bio Nebraska, celebrated their tenth anniversary of production at their Blair, Nebraska facility.
Welcome AdvaMed
We are excited to welcome new Bio Nebraska member, AdvaMed.
Applications now open for Tech Transfer Boot Camp 2022
UNeMed, a member of Bio Nebraska, is accepting applications for its 2022 Technology Transfer Boot Camp.
Midlands Voices: Support for entrepreneurship is the solution to a vibrant Nebraska
Catherine Lang, state director of the Nebraska Business Development Center, co-authored a recent op-ed with Tim Mittan, District Director for the Nebraska District SBA Office, about the importance of small business in Nebraska. The Nebraska Business Development Center is a member of Bio Nebraska.
NMotion Growth Accelerator Accepting Applications
NMotion, a member of Bio Nebraska, is accepting applications for their 2022 Growth Accelerator. Applications for the $100,000 investment are due May 30, 2022.
U.S. Food and Drug Administration Approves Camzyos™
Bristol Myers Squibb, a member of Bio Nebraska, announced last week that the FDA approved Camzyos™ for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.